Eli Lilly is set to sign a deal worth up to $2 billion with Hong Kong-listed Insilico Medicine to develop new treatments and commercialise a diabetes drug. According to a report by a global publication, the agreement includes an upfront payment of $115 million and additional payouts tied to regulatory approvals and sales milestones.
As part of the partnership, Eli Lilly will gain exclusive rights to sell a GLP-1 drug developed by Insilico Medicine for diabetes treatment. The deal is expected to be formally announced soon, although the details have not yet been independently verified. Both companies have not responded to requests for comment so far.
The collaboration reflects a growing shift in the pharmaceutical industry towards using AI to speed up research and development. Companies are increasingly adopting advanced modelling tools and automated laboratory systems to improve efficiency across drug discovery pipelines.
This move also aligns with efforts by the U.S. Food and Drug Administration to reduce reliance on animal testing in the near future, encouraging the use of innovative technologies in drug development.
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream LinkedIn | The Mainstream Facebook | The Mainstream Youtube | The Mainstream Twitter
About us:
The Mainstream is a premier platform delivering the latest updates and informed perspectives across the technology business and cyber landscape. Built on research-driven, thought leadership and original intellectual property, The Mainstream also curates summits & conferences that convene decision makers to explore how technology reshapes industries and leadership. With a growing presence in India and globally across the Middle East, Africa, ASEAN, the USA, the UK and Australia, The Mainstream carries a vision to bring the latest happenings and insights to 8.2 billion people and to place technology at the centre of conversation for leaders navigating the future.
